David Birch

David Birch

Retina Foundation of the Southwest, Dallas, Georgia, USA
orcid

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1999 in Cell
Verified
Journal Article
Closed access
JWJian Weng
Jian Weng
NMNathan L. Mata
Nathan L. Mata
SASassan M. Azarian
Sassan M. Azarian
RTRadouil Tzekov
Radouil Tzekov
David BirchDavid Birch
David Birch
GTGabriel H. Travis
Gabriel H. Travis

1 November 1990 in Pediatric Research
Verified
Journal Article
Closed access
RURicardo D Uauy
Ricardo D Uauy
David BirchDavid Birch
David Birch
EBEileen E Birch
Eileen E Birch
JTJon E Tyson
Jon E Tyson
DHDennis R Hoffman
Dennis R Hoffman

1 March 2000 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
EBEileen E Birch
Eileen E Birch
SGSharon Garfield
Sharon Garfield
DHDennis R Hoffman
Dennis R Hoffman
RURicardo Uauy
Ricardo Uauy
David BirchDavid Birch
David Birch
The effects of dietary docosahexaenoic acid (DHA) supply during infancy on later cognitive development of healthy term infants were evaluated in a randomized clinical trial of infant formula milk supplemented with 0.35% DHA or with 0.36% DHA and 0.72% arachidonic acid (AA), or control formula which provided no DHA or AA. Fifty-six 18-month-old children (26 male, 30 female) who were enrolled in the trial within the first 5 days of life and fed the assigned diet to 17 weeks of age were tested using the Bayley Scales of Infant Development, 2nd edition (BSID-II) (Bayley 1993) at the Retina Foundation of the Southwest, Dallas, TX. These children had also been assessed at 4 months and 12 months of age for blood fatty-acid composition, sweep visual evoked potential (VEP) acuity, and forced-choice preferential looking (FPL) acuity (Birch et al. 1998). Supplementation of infant formula with DHA+AA was associated with a mean increase of 7 points on the Mental Development Index (MDI) of the BSID-II. Both the cognitive and motor subscales of the MDI showed a significant developmental age advantage for DHA- and DHA+AA-supplemented groups over the control group. While a similar trend was found for the language subscale, it did not reach statistical significance. Neither the Psychomotor Development Index nor the Behavior Rating Scale of the BSID-II showed significant differences among diet groups, consistent with a specific advantage of DHA supplementation on mental development. Significant correlations between plasma and RBC-DHA at 4 months of age but not at 12 months of age and MDI at 18 months of age suggest that early dietary supply of DHA was a major dietary determinant of improved performance on the MDI.

1 August 1998 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
EBEileen E Birch
Eileen E Birch
DHDennis R Hoffman
Dennis R Hoffman
RURicardo Uauy
Ricardo Uauy
David BirchDavid Birch
David Birch
CPClaude Prestidge
Claude Prestidge

1 September 2001 in Lipids
Verified
Journal Article
Closed access
PDF file
RURicardo Uauy
Ricardo Uauy
DHDennis R. Hoffman
Dennis R. Hoffman
PPPatricio Peirano
Patricio Peirano
David BirchDavid Birch
David Birch
EBEileen E. Birch
Eileen E. Birch

1 October 2016 in Ophthalmology
Verified
Journal Article
Open access
LCLyndon da Cruz
Lyndon da Cruz
JDJessy D. Dorn
Jessy D. Dorn
MHMark S. Humayun
Mark S. Humayun
GDGislin Dagnelie
Gislin Dagnelie
JHJames Handa
James Handa
RGRobert J. Greenberg
Robert J. Greenberg
The Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) was developed to restore some vision to patients blind as a result of retinitis pigmentosa (RP) or outer retinal degeneration. A clinical trial was initiated in 2006 to study the long-term safety and efficacy of the Argus II System in patients with bare or no light perception resulting from end-stage RP. Prospective, multicenter, single-arm clinical trial. Within-patient controls included the nonimplanted fellow eye and patients' native residual vision compared with their vision with the Argus II. Thirty participants in 10 centers in the United States and Europe. The worse-seeing eye of blind patients was implanted with the Argus II. Patients wore glasses mounted with a small camera and a video processor that converted images into stimulation patterns sent to the electrode array on the retina. The primary outcome measures were safety (the number, seriousness, and relatedness of adverse events) and visual function, as measured by 3 computer-based, objective tests. Secondary measures included functional vision performance on objectively scored real-world tasks. Twenty-four of 30 patients remained implanted with functioning Argus II Systems at 5 years after implantation. Only 1 additional serious adverse event was experienced after the 3-year time point. Patients performed significantly better with the Argus II on than off on all visual function tests and functional vision tasks. The 5-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind as a result of RP. The Argus II is the first and only retinal implant to have market approval in the European Economic Area, the United States, and Canada.